MetaCap

Aptevo Therapeutics (APVO) vs PRF Technologies (PRFX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PRF Technologies is the larger company by market cap ($1.7 million vs $1.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APVO-78.04%PRFX-45.79%
+4%-39%-82%
Oct 7, 20261 yearNov 20, 2026
APVO-77.42%PRFX-45.86%
+4%-39%-81%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APVO versus PRFX key metrics
MetricAPVOPRFX
Share price$0.4041$0.4758
Market cap$1.40M$1.66M
1-day change-2.37%-23.68%
P/E ratio (TTM)0.01—
EPS (TTM)$66.96$-4.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$17.00K
Net income (latest FY)$-25.97M$-5.02M
Gross margin—-311.76%
Operating margin—-30129.41%
Net margin—-29541.18%
52-week high$25.56$7.95
52-week low$0.377$0.46
Distance from 52-week high-98.42%-94.02%
Analyst consensusnone—
Avg. price target upside+6210.32%—
Average volume132.90K228.55K
Shares outstanding3.46M3.50M
Employees336
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aptevo Therapeutics

APVO stock →

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About PRF Technologies

PRFX stock →

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

APVO vs PRFX FAQ

Which is bigger, Aptevo Therapeutics or PRF Technologies?

PRF Technologies (PRFX) is larger, with a market capitalization of $1.66M compared with $1.40M for Aptevo Therapeutics (APVO).

Are Aptevo Therapeutics and PRF Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons